Bfsg LLC Sells 2,143 Shares of Pfizer Inc. (NYSE:PFE)

by · The Cerbat Gem

Bfsg LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 0.8% during the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 273,172 shares of the biopharmaceutical company’s stock after selling 2,143 shares during the period. Pfizer makes up approximately 0.9% of Bfsg LLC’s holdings, making the stock its 26th biggest holding. Bfsg LLC’s holdings in Pfizer were worth $7,906,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. Olistico Wealth LLC acquired a new position in shares of Pfizer during the second quarter worth about $25,000. MFA Wealth Advisors LLC acquired a new position in Pfizer during the 2nd quarter worth approximately $29,000. Quarry LP bought a new position in shares of Pfizer during the 2nd quarter worth approximately $31,000. Trivant Custom Portfolio Group LLC raised its holdings in shares of Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 600 shares during the last quarter. Finally, Financial Connections Group Inc. bought a new stake in shares of Pfizer in the second quarter worth $34,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts recently weighed in on the stock. StockNews.com raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Wednesday, October 9th. Barclays raised their price objective on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Wells Fargo & Company raised their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research note on Wednesday, July 31st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Thursday, October 3rd. Six analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $34.10.

Get Our Latest Research Report on PFE

Pfizer Stock Performance

Shares of NYSE PFE opened at $29.66 on Thursday. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $33.19. The stock has a 50 day moving average of $29.04 and a 200-day moving average of $28.42. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. The company has a market capitalization of $168.07 billion, a P/E ratio of -494.33, a P/E/G ratio of 1.30 and a beta of 0.67.

Pfizer (NYSE:PFE – Get Free Report) last posted its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion during the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter last year, the company posted $0.67 EPS. Pfizer’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, equities research analysts predict that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be given a $0.42 dividend. This represents a $1.68 annualized dividend and a dividend yield of 5.66%. The ex-dividend date is Friday, November 8th. Pfizer’s payout ratio is -2,800.00%.

About Pfizer

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Featured Stories

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Free Report).